Fig. 2: PFS and DFS benefits of dual ER/HER2 blockade in key phase 2 and 3 clinical trials. | npj Breast Cancer

Fig. 2: PFS and DFS benefits of dual ER/HER2 blockade in key phase 2 and 3 clinical trials.

From: Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer

Fig. 2

Error bars indicate 95% CI. AI aromatase inhibitor; CI confidence interval; DFS disease-free survival; ER estrogen receptor; HER2 human epidermal growth factor receptor 2; HR hormone receptor; PFS progression-free survival; TTP time to progression.

Back to article page